What's the deal with this battered breast cancer biotech and is it a good deal?
News & Analysis: Puma Biotechnology
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
A large percentage of patients prescribed the biotech's lone drug stop taking it early. Can two changes to its dosing protocols solve that problem?
PBYI earnings call for the period ending September 30, 2019.
Investors are eager to see how Nerlynx is faring in light of a high discontinuation rate among patients and a recent label supplement that could reverse the trend.
These three beaten-down cancer stocks could prove to be amazing value plays.
An analyst downgrade and a departing executive make for a bad day.
PBYI earnings call for the period ending June 30, 2019.
Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?
The market's shortsightedness has it missing the long-term upside at this biotech, logistics specialist, and pipeline company.